Semaglutide for Weight Loss in Low Responders After Bariatric Surgery

We are studying whether Semaglutide 2.4 mg can help individuals who haven't lost enough weight after bariatric surgery. This trial compares its effects with a placebo to see how it impacts weight loss and overall health.

1-2 years >20 visits Monitoring phase (IV)Standard Medicines InjectionDiabetologyEndocrinologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Semaglutide

Semaglutide is a substance that helps lower blood sugar in people with type 2 diabetes and can also reduce appetite to aid weight loss.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Rode Kruis Ziekenhuis B.V.

Surgery

Beverwijk, Netherlands

Zuyderland Medisch Centrum Stichting

Surgery

Heerlen, Netherlands

Sint Antonius Ziekenhuis Stichting

Surgery

Nieuwegein, Netherlands

Sponsor: Stichting Zuyderland Medisch Centrum

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.